Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Endovascular Treatment · 1 trial · 3 indications
The mRS Score ranges from 0-6 and describes the degree of disability or dependence after a stroke. The grades are no symptoms (0), no significant disability (1), slight disability (2), moderate disability (3), moderately severe disability (4), severe disability (5), and death (6).
| Arm | Type | Description |
|---|---|---|
| Favorable CIS | OTHER | Patients with a favorable CIS (fCIS) will receive endovascular treatment (EVT) and medical treatment consistent with national guidelines. |
| Poor CIS | EXPERIMENTAL | Patients with a poor CIS (pCIS) will receive endovascular treatment (EVT) and medical treatment consistent with national guidelines. |
| Name | Type | Description |
|---|---|---|
| Endovascular Treatment (EVT) | PROCEDURE | EVT is an endovascular procedure in which a catheter is inserted into an artery and directed to the site of the blocked blood vessel in the brain. The clot is removed using a mechanical device with or without an injection of tPA (tissue plasminogen activator) directly at the site of the clot. The protocol calls for use of the Trevo stent retriever (Stryker Neurovascular) for the first pass of clot removal. |
Inclusion Criteria: 1. Anterior circulation acute ischemic stroke due to blockage of the intracranial internal carotid artery or middle cerebral artery (M1) 2. Within 24 hours of onset of symptoms 3. NIHSS Score is 8 or greater Exclusion Criteria: 1. Contra-indication for IAT found on initial CT ...
Endovascular Treatment is an investigational therapy being studied for use in Acute Stroke, specifically in patients with Brain Ischemia and Ischemic Stroke. It is a controlled, double-blind intervention that was evaluated in a Phase 1 clinical trial in the United States. The treatment is not yet approved and remains in clinical development.
Endovascular Treatment is being developed by Stryker Corporation, a medical technology company traded on the NYSE under the ticker SYK. Stryker is conducting clinical research on this therapy for Acute Stroke, including a completed Phase 1 trial in the United States.
Endovascular Treatment is in Phase 1 clinical development. A Phase 1 trial, known as The Capillary Index Score Trial, has been completed. The therapy is investigational and has not been approved by regulatory authorities. It is being studied for Acute Stroke and related ischemic conditions.
Endovascular Treatment has been studied in one clinical trial, NCT02618031, titled The Capillary Index Score Trial. This Phase 1 study was completed and enrolled 57 participants with Acute Stroke, Brain Ischemia, or Ischemic Stroke. The trial was conducted in the United States and included adults aged 18 years and older.
Endovascular Treatment is not FDA approved. It is an investigational therapy that has completed a Phase 1 clinical trial for Acute Stroke. The therapy is still in clinical development, and its safety and efficacy have not been established for regulatory approval.